Zhao Miaomiao, Ren Longbing, Zhou Zhitong, Wang Tao, Li Jue
School of Clinical Medicine, Shanghai University of Medicine and Health Sciences, Shanghai, People's Republic of China.
Department of Epidemiology, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, People's Republic of China.
Clin Epidemiol. 2022 Jun 25;14:779-788. doi: 10.2147/CLEP.S360395. eCollection 2022.
The effects of statins on renal outcomes have already been studied in patients with chronic kidney disease (CKD); however, data on the general population are limited. We evaluated the association between statin use and risk of CKD in community-dwelling older people in Shanghai, China.
This registry-based cohort study was conducted in four communities in four districts in Shanghai. Participants with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m in 2016 were eligible for the study, and new-onset CKD in 2017, 2018, and 2019 was recorded. Poisson generalized linear models were conducted to examine the relationships among statin therapy, dyslipidemia, and CKD; linear mixed-effects models were conducted to examine the relationships between statin therapy and changes in eGFR. All analyses were performed with both conventional adjustment and propensity score-matching methods.
Of the study cohort of 2455 participants (41.1% men; average age, 68.06 years), 624 (25.4%) were treated with stains. Two propensity score-matched cohorts of 604 participants each were analyzed (statin users and nonusers). Statin use was significantly associated with a decreased risk of new-onset CKD with hazard ratios (HRs) and 95% confidence intervals (CIs) of 0.73 (0.59 to 0.91) (<0.01) in the unmatched cohort and 0.75 (0.59 to 0.97) (=0.02) in the matched cohort. There were significant differences in the eGFR decline between statin users and nonusers from baseline to 3 years in the unmatched and matched cohorts (both <0.05). In addition, both statin users and nonusers with dyslipidemia experienced more new-onset CKD (both <0.05).
Statin use was significantly associated with a decreased risk of new-onset CKD and a slower decline in eGFR in community-dwelling older people. Meanwhile, dyslipidemia was a risk factor for CKD progression among both statin users and nonusers.
他汀类药物对慢性肾脏病(CKD)患者肾脏结局的影响已得到研究;然而,关于普通人群的数据有限。我们评估了中国上海社区居住老年人使用他汀类药物与CKD风险之间的关联。
这项基于登记的队列研究在上海四个区的四个社区进行。2016年估算肾小球滤过率(eGFR)≥60 mL/min/1.73 m²的参与者符合研究条件,并记录2017年、2018年和2019年新发生的CKD情况。采用泊松广义线性模型来检验他汀类药物治疗、血脂异常和CKD之间的关系;采用线性混合效应模型来检验他汀类药物治疗与eGFR变化之间的关系。所有分析均采用传统调整方法和倾向评分匹配法进行。
在2455名参与者的研究队列中(男性占41.1%;平均年龄68.06岁),624人(25.4%)接受了他汀类药物治疗。对两个倾向评分匹配队列(各604名参与者)进行了分析(他汀类药物使用者和非使用者)。在未匹配队列中,使用他汀类药物与新发CKD风险降低显著相关,风险比(HRs)和95%置信区间(CIs)为0.73(0.59至0.91)(P<0.01),在匹配队列中为0.75(0.59至0.97)(P=0.02)。在未匹配和匹配队列中,从基线到3年,他汀类药物使用者和非使用者的eGFR下降存在显著差异(均P<0.05)。此外,血脂异常的他汀类药物使用者和非使用者发生新发CKD的情况均更多(均P<0.05)。
在社区居住的老年人中,使用他汀类药物与新发CKD风险降低及eGFR下降较慢显著相关。同时,血脂异常是他汀类药物使用者和非使用者中CKD进展的一个危险因素。